CGTLive’s Weekly Rewind – January 12, 2024
Review top news and interview highlights from the week ending January 12, 2024.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. FDA Activity Recap: December 2023 Features 2 Major Approvals, Meetings, and Clinical Holds
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.
2. Mazyar Shadman, MD, on Investigating Treatment Choices With CAR-T and Auto-HSCT in LBCL
The associate professor at Fred Hutch Cancer Center discussed data from a retrospective analysis of patients treated with tisa-cel, axi-cel, or liso-cel.
3. Myasthenia Gravis mRNA CAR-T Demonstrates Clinically Meaningful Improvements in Phase 2a Trial
In terms of safety, Descartes-08 was characterized as well-tolerated during the study and long-term follow-up period.
4. Tami John, MD, on the FDA Approvals of Exa-cel and Lovo-cel
The clinical associate professor at Stanford Medicine also discussed ongoing trends in sickle cell disease research.
5. Vertex and CRISPR’s Ongoing Trial for Sickle Cell Disease Gene Therapy Seeks to Gather Patient Reported Outcomes
Exa-cel was recently approved for the treatment of SCD in the US, but data from the pivotal clinical trial continues to be collected.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025